Chaewon Hwang, M.D.
@ChaewonHwangMD
Followers
29
Following
72
Media
15
Statuses
77
Radiation Oncology, PGY-4 @TuftsMedicalCtr & @BIDMCHealth | Chief Resident 25' - 26' | MD @RWJMS | BSc @UofR | 26.2 x 3 🏃♀️🦄🗽 | Berlin 🇩🇪 loading... 🏃♀️
Boston, MA
Joined March 2023
RT @ACRORadOnc: #CURiEAlert: “Cardiac SBRT for Refractory Ventricular Tachycardia Using Innovative Motion Tracking w/ Electroanatomical Map….
0
2
0
RT @ASCO: Want to share practice-changing research from #ASCO25 with your patients? 18 summaries highlighting key studies in #BreastCancer,….
0
18
0
RT @KrishanJethwa: 🚨ESOPEC, Patterns of Recurrence🚨. 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%)….
0
39
0
Camizestrant + CDK4/6 inhibitor, as opposed to continuation of AI + CDK4/6, at first sign of ESR1 mutation detected via ctDNA, led to improved PFS. Exciting frontiers in incorporation of #ctDNA !.
0
0
0
Day 3 of #ASCO25! Exciting plenary session presentation and simultaneous publication, "First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer" | New England Journal of Medicine
1
1
3
RT @TuftsMCResearch: #ASCO25 today: #TuftsMedicine @tuftsmcradonc's @ChaewonHwangMD presents in Hall A - Posters, 9 AM to noon CT: How soci….
0
1
0
Thank you @ACRORadOnc for this publishing opportunity, through #CURiE ! I had the pleasure of presenting this unique case at #ACRO2025. And thank you to my coresidents, Raj and Alvin, for your help!.
#CURiEAlert: "A Unique Case Presentation of Synchronous Early-Stage Invasive Lobular Carcinoma of the Breast & Marginal Zone Lymphoma of the Ipsilateral Breast" by ACRO member @ChaewonHwangMD, w/ @AKrishnaMD, Raj Kavadi & Kara Lynne Leonard, is published:
0
1
4
RT @ASCO: Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions t….
0
45
0
Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months:.➡️ recurrence-free survival at 2 years was 92%. #AACR25 #oncology #research.
Presented at #AACR25:. Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: . @AACR
0
0
4
RT @DanaFarberNews: In the first advance in 20+ years for pts with locally advanced #HeadAndNeckCancer, a phase 3 clinical trial presented….
0
13
0
Really helpful guide as I am learning to respond to reviewers, submitting my research to journals:
🎖️Trainees in oncology and across all fields of medicine! Do not miss this manuscript on how to effectively respond to reviewer comments!. Thanks @VickersBiostats @redunndant @cgratzke @MRoupret @Albert0Briganti et al. @EUplatinum @EurUrolFocus @EurUrolOncol 🙏. @OncoAlert
0
0
0
Excited to be presenting our research @ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT: @TuftsMCResearch @BIDMC_CancerCtr.
0
1
2
📣Big shoutout to our faculty members @TuftsMedicalCtr & @BIDMChealth radiation onology residency, Dr. Jang and Dr. Huber, for being a speaker and moderator at this year's @ASTRO_org Refresher Course! Thank you for all that you do for us and for the #radonc community
0
1
4
📣 On the importance of specialty representation in committees for treatment recommendation and management of cancer 👏👏👏.
REPRESENTATION MATTERS!. Study finds that members of NCCN committees include:.48%- med onc.21%- surg onc.9%- rad onc (3% Chair; 23% VC). Emphasizes opportunity for growth as specialty inclusivity is critical to balance diversity of perspectives in management recommendations
0
0
0